Opsens Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Louis Laflamme CPA, CPA
- Full Time Employees
- 293
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 750 Boulevard du Parc Technologique Québec QC Canada G1P 4S3
- IPO Date
- Aug 3, 2012
- Website
- opsens.com
- Similar Companies
- Business
- Opsens Inc. (OTCQX: OPSSF; TSX: OPS) develops, manufactures, and commercializes innovative medical devices focused on guidewires and optical sensors for minimally invasive cardiovascular procedures, including fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) measurements; the company offers products such as the OptoWire and OptoProbes for pressure and temperature sensing, MicroWire for coronary physiology, SavvyWire for transcatheter aortic valve replacement (TAVR) guidance, and related consoles and software platforms. Founded in 2007 and headquartered in Quebec City, Canada, Opsens operates primarily in North America and Europe, serving interventional cardiologists and hospitals through direct sales and distribution partners in the cardiovascular medical device segment. The company targets acute and chronic coronary artery disease markets, providing fiber optic-based sensors that deliver high-fidelity hemodynamic data with reduced signal drift compared to traditional pressure wires. In recent developments, Opsens secured FDA clearance for its SavvyWire Leader in June 2024, expanding its TAVR portfolio; the company also completed a strategic financing round in late 2023 to support U.S. market penetration and reported positive clinical results from the SAFE-TAVI trial demonstrating SavvyWire's procedural efficiencies. Additionally, Opsens announced a distribution agreement with MedAlliance in 2024 to broaden access to its FFR products in select European regions and underwent a ticker symbol change on the TSX to reflect its growing U.S. presence.
Opsens (OTCMKTS:OPSSF) Stock Price Crosses Below 200 Day Moving Average – What’s Next?
Opsens stock soars on takeover deal with Haemonetics
Haemonetics Corporation Announces Definitive Agreement to Acquire OpSens, Inc.
Opsens Inc. (OPSSF) Q3 2023 Results - Earnings Call Transcript
OpSens Announces Participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference
OpSens shares climb following record 1Q revenue surge
Opsens Inc. (OPSSF) Q1 2023 Earnings Call Transcript
Opsens Inc. (OPSSF) Q4 2022 Earnings Call Transcript
Opsens Inc. (OPSSF) CEO Louis Laflamme on Q3 2022 Results - Earnings Call Transcript
Opsens Inc.'s (OPSSF) CEO Louis Laflamme on Q2 2022 Results - Earnings Call Transcript
Opsens Inc.'s (OPSSF) CEO Louis Laflamme on Q1 2022 Results - Earnings Call Transcript
Opsens Inc. (OPSSF) CEO Louis Laflamme on Q4 2021 Results - Earnings Call Transcript
Opsens Inc. (OPSSF) CEO Louis Laflamme on Q3 2021 Results - Earnings Call Transcript
Opsens: The Making Of A Diversified Medical Technology Company